These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 11834972)

  • 41. Experience with efavirenz in end-stage renal disease.
    Das S; Ghanem M; Huengsberg M
    Int J STD AIDS; 2004 Feb; 15(2):143. PubMed ID: 15006080
    [No Abstract]   [Full Text] [Related]  

  • 42. Recreational substance use and tolerance of efavirenz in HIV-1 infected patients.
    Faggian F; Lattuada E; Lanzafame M; Antolini D; Concia E; Vento S
    AIDS Care; 2005 Oct; 17(7):908-10. PubMed ID: 16120507
    [TBL] [Abstract][Full Text] [Related]  

  • 43. New expanded access drugs for use in combination therapy.
    Notes Undergr; 1998; (No 37):suppl 1-2. PubMed ID: 11365823
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Permanent blindness after cyclosporine neurotoxicity in a kidney-pancreas transplant recipient.
    Esterl RM; Gupta N; Garvin PJ
    Clin Neuropharmacol; 1996 Jun; 19(3):259-66. PubMed ID: 8726545
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Periconceptional exposure to efavirenz and neural tube defects.
    De Santis M; Carducci B; De Santis L; Cavaliere AF; Straface G
    Arch Intern Med; 2002 Feb; 162(3):355. PubMed ID: 11822930
    [No Abstract]   [Full Text] [Related]  

  • 46. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study.
    van Leth F; Phanuphak P; Ruxrungtham K; Baraldi E; Miller S; Gazzard B; Cahn P; Lalloo UG; van der Westhuizen IP; Malan DR; Johnson MA; Santos BR; Mulcahy F; Wood R; Levi GC; Reboredo G; Squires K; Cassetti I; Petit D; Raffi F; Katlama C; Murphy RL; Horban A; Dam JP; Hassink E; van Leeuwen R; Robinson P; Wit FW; Lange JM;
    Lancet; 2004 Apr; 363(9417):1253-63. PubMed ID: 15094269
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Severe CNS side-effect and persistent high efavirenz plasma levels in a patient with HIV/HCV coinfection and liver cirrhosis.
    Bickel M; Stephan C; Rottmann C; Carlebach A; Haberl A; Kurowski M; Staszewski S
    Scand J Infect Dis; 2005; 37(6-7):520-2. PubMed ID: 16012018
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Severe psychosis in an African woman due to the antiretroviral agent efavirenz].
    Oudijn MS; Vrijlandt CM; Casteelen G
    Ned Tijdschr Geneeskd; 2006 Mar; 150(11):643-4; author reply 644. PubMed ID: 16610510
    [No Abstract]   [Full Text] [Related]  

  • 49. [Progress in HIV therapy. Effective and simple therapy with efavirenz].
    MMW Fortschr Med; 2001 Apr; 143 Suppl 1():36-7. PubMed ID: 11373774
    [No Abstract]   [Full Text] [Related]  

  • 50. Pharmacokinetic interactions between efavirenz and rifampicin in the treatment of HIV and tuberculosis: one size does not fit all.
    Brennan-Benson P; Lyus R; Harrison T; Pakianathan M; Macallan D
    AIDS; 2005 Sep; 19(14):1541-3. PubMed ID: 16135909
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacokinetic interaction of amprenavir in combination with efavirenz or delavirdine in HIV-infected children.
    Wintergerst U; Engelhorn C; Kurowski M; Hoffmann F; Notheis G; Belohradsky BH
    AIDS; 2000 Aug; 14(12):1866-8. PubMed ID: 10985332
    [No Abstract]   [Full Text] [Related]  

  • 52. [Apropos of atypical melancholia with Sustiva (efavirenz)].
    Lang JP; Halleguen O; Picard A; Lang JM; Danion JM
    Encephale; 2001; 27(3):290-3. PubMed ID: 11488260
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The first case of efavirenz-induced photosensitivity in a Japanese patient with HIV infection.
    Yoshimoto E; Konishi M; Takahashi K; Murakawa K; Maeda K; Mikasa K; Yamashina Y
    Intern Med; 2004 Jul; 43(7):630-1. PubMed ID: 15335197
    [No Abstract]   [Full Text] [Related]  

  • 54. Sustiva: revised drug-interaction information.
    AIDS Treat News; 2006; (421):5. PubMed ID: 17407831
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safe substitution for efavirenz.
    AIDS Patient Care STDS; 2004 Jan; 18(1):58. PubMed ID: 15080097
    [No Abstract]   [Full Text] [Related]  

  • 56. 48-week data released for combination treatment with efavirenz.
    AIDS Patient Care STDS; 1999 Jul; 13(7):438-40. PubMed ID: 10870602
    [No Abstract]   [Full Text] [Related]  

  • 57. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection.
    Csajka C; Marzolini C; Fattinger K; Décosterd LA; Fellay J; Telenti A; Biollaz J; Buclin T
    Clin Pharmacol Ther; 2003 Jan; 73(1):20-30. PubMed ID: 12545140
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Summaries for patients. Neuropsychological side effects of efavirenz.
    Ann Intern Med; 2005 Nov; 143(10):I43. PubMed ID: 16287787
    [No Abstract]   [Full Text] [Related]  

  • 59. Cortisol serum levels and their relationship to certain antiretroviral drugs.
    Collazos J; Ibarra S; Loureiro M
    Scand J Infect Dis; 2004; 36(6-7):480-2. PubMed ID: 15307572
    [TBL] [Abstract][Full Text] [Related]  

  • 60. First once-daily drug simplifies dosing, offers new options in HIV-1 treatment.
    AIDS Alert; 1998 Nov; 13(11):121-4. PubMed ID: 11365967
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.